Xencor reports promising kidney cancer drug results, plans late-stage trial
Seeking Alphavia NewsData.io
Xencor reports promising early kidney cancer drug data, with XmAb819 shrinking tumors in 45.5% of patients.
Headline and summary provided via NewsData.io. The full article and its copyright belong to the original publisher.